- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Florbetapir, PET/MR and Other Nuclear Medicine Highlights
In honor of Nuclear Medicine Week, the Society of Nuclear Medicine and Molecular Imaging highlights four major advancements in the field.
It’s Nuclear Medicine Week, which means it’s a good time to reflect on some major advances in the field this year.
The Society of Nuclear Medicine and Molecular Imaging and the SNMMI Technologist Section compiled a list of four highlights:
• FDA’s approval of florbetapir for amyloid imaging
• The first results of PET/MR in clinical use
• Dose optimization efforts, including Image Gently’s guidelines for nuclear medicine
• Increased use of molecular breast imaging
Looking forward to next year, the society noted that appropriate use criteria for amyloid imaging will be released, and the FDA is expected to approve radium-223 for treatment of recurrent prostate cancer. “We are hopeful that several other radiotracers will be approved by the FDA in the coming year as well,” Frederic H. Fahey, DSc, SNMMI president, said in a statement. “In addition, SNMMI’s global initiative will also be well underway and a worldwide collaboration will be in place to advance the field.”
What are some other notable nuclear medicine moments from this year?
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
FDA Expands Clearance of MRI-Guided AI Platform for Deep Brain Stimulation and Lesioning Techniques
September 3rd 2024Utilizing a new machine learning model, the OptimMRI software may improve radiosurgery applications and lesioning techniques such as MRI-guided focused ultrasound through enhanced targeting of the inferolateral part of the ventral intermediate nucleus (VIM).
New Research Highlights Emerging MRI Contrast Agent for Bladder Imaging
August 21st 2024A new MRI contrast agent may provide a viable non-invasive alternative for the detection of interstitial cystitis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.
